JOHNSON & JOHNSON is 399.5x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($573.98 B vs $1.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KALV | JNJ |
|---|---|---|
| Market cap | $1.44 B | $573.98 B |
| US-listed rank | #2363 | #20 |
| Revenue (latest FY) | $50.00M | $94.19B |
| Net income (latest FY) | -$183.40M | $26.80B |
| Net margin | -366.8% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 834 | 984 |
JOHNSON & JOHNSON is 399.5x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($573.98 B vs $1.44 B).
In their latest fiscal years, KalVista Pharmaceuticals, Inc. reported $50.00M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: KalVista Pharmaceuticals, Inc. and JOHNSON & JOHNSON, or browse the full rankings.